During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community ...

Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...

The FDA has granted a priority review to dordaviprone for treating patients with recurrent H3K27M-mutant diffuse glioma, a ...

Panelists discuss the use of RNA-based molecular panels in metastatic non–-small cell lung cancer (NSCLC), highlighting their ...

Studies from Munich University highlighted quality of life in bladder and prostate cancer at ASCO 2025 Genitourinary Cancers ...

The FDA granted Regenerative Medicine Advanced Therapy designation to NXC-201 for the treatment of relapsed/refractory light ...